Introduction
Although cancer incidence rates in women less than 50years old continue to increase during recent years, mortality rates are dramatically decreasing due to modern advances in treatment. Modern techniques for prevention of treatment -Induced Ovarian ablation include better shielding of the ovaries from the damaging effects of radiation. This can be accomplished by implementing transposition procedures to move the ovaries outside of the area at risk. In addition knowledge of the precise three dimensional location of the ovaries allow the physician to limit the dose in these regions with novel beam arrangements, three dimensional conformal radiation therapy or Intensity modulated radiation Therapy. Prevention of the cytotoxic effects of the chemotherapy by administering a concurrent GnRHagonist (GnRHa) appears to be promising. In modern era of the improved antineoplastic age and highly conformal, three dimensional planned radiation therapy , the possibility of limiting the ovaries from the excess treatment-related toxicity in certain situations is becoming more of a reality.
II. Treatment Methods

Follicle -Stimulating Hormone (FSH)
FSH stimulates the growth and recruitment of immature ovarian follicles in the ovary. In early (small) antral follicles, FSH is the major survival factor that rescues the small antral follicles (2-5 mm in diameter for humans)from apoptosis programmed death of the somatic cells of the follicle and oocyte .In addition , gonadotropin surge -attenuating factor produced by small follicles during the first half of the follicles phase also exerts a negative feedback on pulsatile luteinizing hormone (LH)secretion amplitude thus allowing a more favorable environment for follicle growth and preventing premature luteinization.
Estradiol
In the females, estradiol acts as a growth hormone for tissue of the reproductive organs, supporting the lining of the vagina, the cervical glands, the endometrium and the lining of the fallopian tubes. It enhances growth of the myometrium. Estradiol appears necessary to maintain oocytes in the ovary. During the menstrual cycle, estradiol produced by the growing follicle triggers, via a positive feedback system, the hypothalamicpituitary events that lead to the luteinizing hormone surge, inducing ovulation. The development of secondary sex characteristics in women is driven by estradiol. Estradiol produces breast development, and is responsible for changes in the body shape, affecting bones, joints and fat deposition.
Preliminary Design: (concepts)
Premenopausal women treated for Hodgkin and non Hodgkin Lymphoma were given three to eight cycles of chemotherapy or high dose therapy. At the time of random experiment it was observed that FSH and estradiol levels were less. Eligible patients were randomly assigned to receive chemotherapy and high dose therapy. The treatment was initiated 10days before the start of chemotherapy if possible. FSH and estradiol levels were measured in each center before the start of treatment, after 10 days ,after 3 months and at the end of DOI: 10.9790/5728-1204025661 www.iosrjournals.org 57 | Page the chemotherapy treatment .During the follow up period ,FSH and estradiol levels were evaluated at 3,6 and 12 months. According to the oncologists recommendation the patients were allowed to take oral contraception or other hormonal replacement therapy during the follow-up period. However FSH and estradiol levels were tested at least 10 days after the suspension of the medication. For the remaining patients the blood tests were preferentially performed at the beginning of the menstrual cycle. Treatment -related adverse effects were monitored at each visit. The above Time points considered at inclusion, after 3 months of chemotherapy, at completion of chemotherapy and at 3,6 and 12 months of follow up with GnRHa(Gonadotropin releasing hormone agonist)
III. Indentations and Equations
FSH and Estradiol Levels for GnRHa Group and Control Group
Percentage of women with follicle stimulating hormone (FSH) and estradiol values. (2001), we would like to incorporate in the bivariate model the retention of univariate RHR structure. Thus, functional forms of al (X 1 ) and a2(X 2 ) are the two basic structures that one should retain in the bivariate system and this retention should logically be in terms of the corresponding bivariate RHRs. Let F(X 1 , X 2 ) be the distribution function of X = (X 1 , X 2 ). We propose that the corresponding bivariate RHRs be defined by Where A(X 1 ,X 2 ) = -logF(X 1 ,X 2 ) Is the bivariate cumulative RHR function.
THEOREM 1: Bivariate RHRs are locally proportional to the corresponding variate RHRs if the bivariate distribution function is of the form
For same γ It may be noted from the above result that the form of the characterized model given at (5.5) can be used for bivariate extension of univariate distributions retaining univariate structure of RHRs. Let us examine the set of values of γ for which (5.5) is a proper distribution function. The following result provides an answer to this problem by specifying the range of values for γ.
THEOREM 2:
The distribution function F (x1,x2) defined through the CE Model at 5.5 is defined if and only if 0≤γ≤1. The corresponding joint density function is given by Regarding the specific applications of the CE model we consider bivariate generalization of inverse exponential distribution, which is of special importance in RHR analysis. The distribution function of an inverse exponential variable, X, is F(x) = exp (-γ/x) so that (1/X) follows an exponential distributions, we note that cumulative RHRs are ƛ1/x1 and ƛ1/x2. Then, from theorem 1 we get the Bivariate Inverse Exponential Distribution as following
IV.
Figures and Tables 
b. Medical Conclusion drawn from Mathematical Model
• Medical conclusion suggests that a long term benefit of GnRHa on fertility of patients who spontaneously experience restoration of ovarian function. Mathematical model in the form of characterized model for bivariate extension gives a proper distribution function i.e. (F (X 1 ,X 2 ) clearly seen in the mathematical graphs) for a given set of different values of γ. From the mathematical model it is clearly seen that combined effects of FSH and estradiol in the GnRHa group are higher than the corresponding control group. This gives a good conclusion to the medical professionals to measure the level of FSH in each chemotherapy treatment with GnRHa after the period of 3,6 and 12 months follow-up.
